Related Experiment Video
Updated: Aug 9, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML
R A Padua1, A McGlynn, H McGlynn
1Hematology Department, University of Wales College of Medicine, Cardiff, UK.
Abstract:
Myelodysplasia (MDS) is a clonal disease, which increases with age, suggesting that multiple steps are required for the evolution of the condition. Approximately 30% of MDS evolve into acute myelogenous leukemia (AML). In this review, we intend to delineate the genetic events, which may drive this sequence and therefore we will focus primarily on cytogenetic abnormalities where the genes have been identified and oncogenes and suppressor genes that have been implicated. In terms of the biological mechanisms, which characterise this process, it is generally thought that the MDS cell has impaired differentiation, and has increased apoptosis. As the disease progresses in addition, the cells have increased proliferation. As the disease evolves, the population of cells, which predominate remain immature, have decreased apoptosis and in many cases, upregulate anti-apoptotic genes and have deregulated proliferation as the number of blast cells increase. Etiological factors, which contribute to the development of leukemia, include therapeutic agents administered for a primary malignancy. The cytogenetic abnormalities, predisposition factors and genes involved in secondary leukemia will also be reviewed.
Insights
Myelodysplasia (MDS) is a clonal disease that can progress to acute myelogenous leukemia (AML). This review details the genetic events and biological mechanisms driving MDS progression and secondary leukemia development.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myelodysplasia (MDS) is a clonal hematopoietic stem cell disorder that increases with age.
- A significant percentage of MDS cases transform into acute myelogenous leukemia (AML).
- Understanding the molecular pathogenesis of MDS is crucial for predicting and preventing AML transformation.
Purpose of the Study:
- To review the genetic events, including cytogenetic abnormalities, oncogenes, and tumor suppressor genes, implicated in MDS evolution.
- To delineate the biological mechanisms underlying MDS progression, such as impaired differentiation, altered apoptosis, and deregulated proliferation.
- To examine etiological factors contributing to secondary leukemia, including therapeutic agents.
Main Methods:
- Literature review focusing on identified genes within cytogenetic abnormalities.
- Analysis of oncogenes and suppressor genes involved in MDS and AML.
- Review of biological mechanisms of cellular dysfunction in MDS.
- Examination of etiological factors for secondary leukemia.
Main Results:
- MDS progression involves multiple genetic events and alterations in cellular behavior.
- Key genetic events include specific cytogenetic abnormalities and mutations in oncogenes and tumor suppressor genes.
- Biological mechanisms involve impaired differentiation, increased apoptosis initially, followed by decreased apoptosis and deregulated proliferation.
- Therapeutic agents can be etiological factors for secondary leukemia.
Conclusions:
- The evolution of MDS to AML is a multi-step process driven by accumulating genetic abnormalities and altered cellular functions.
- Identifying these genetic events and biological mechanisms is essential for understanding MDS pathogenesis.
- Further research into these factors may lead to improved diagnostic and therapeutic strategies for MDS and secondary leukemia.
Related Concept Videos
01:17Karyotyping
02:23Abnormal Proliferation